Print PDF
Axinn Advised Thermo Fisher on $12.5B Acquisition of QIAGEN
March 3, 2020

Axinn represented Thermo Fisher Scientific Inc., the world leader in serving science, in its proposed $12.5 billion acquisition of QIAGEN N.V., a leading global provider of molecular diagnostics and sample preparation technologies. The Axinn antitrust team included partners John Harkrider, Michael Keeley, and Mark Alexander.

By using the Axinn, Veltrop & Harkrider LLP website with cookies enabled on your browser, you agree to our use of cookies during your browsing experience. Learn more about our privacy policy.